ACA's STRENGTH IS REAFFIRMED
ACA announced it has received a $120 million equity investment,
strengthening its capital base considerably. The investment decision
by Bear Stearns Merchant Banking will make it ACA's largest shareholder.
Existing institutional investors had already contributed approximately
$28 million of new equity capital in order to meet Standard &
Poor's requirement to maintain ACA's "A" rating. The Bear
Stearns investment is slated to close during the third quarter of
this year, pending regulatory approval by New York State, at which
time the "A" financial strength rating will be affirmed.
ACA, which insures lower investment grade municipal bonds at the
"A" level, has sought to provide credit enhancement for
smaller or infrequent issuers with positive credit characteristics.
Larger insurers are most interested in standard industry "names,"
whose repeat business they can count on.
ACA's portfolio of insured bonds is carefully monitored by S&P
and must meet criteria for diversification by sector, credit quality,
and geographical distribution, as well as other standards. ACA also
closely watches the performance of its portfolio over time and,
as a condition of insurance, can intervene to correct a weakening
credit situation.
The newly announced equity infusion allows ACA to exceed the statutory
capital requirement, set by S&P to maintain its financial strength
rating. Although ACA was placed on CreditWatch with negative implications
in May 2004, the company has been profitable and its portfolio has
performed as expected. As
we noted back in May, S&P at the time maintained its "A"
rating of the company.
The higher capital levels and lower risk profile favored by ACA's
new management should provide a stable base for the company's long-term
prospects.
ANALYST CERTIFICATION
SEC Regulation AC
I, Jay H. Abrams, hereby certify that the views expressed in this
research report accurately reflect my personal views about the subject
securities and issuers. I also certify that no part of my compensation
was, is, or will be, directly or indirectly, related to the specific
recommendations or view expressed in this report.
07/23/2004
About Dr. Abrams
|